News | September 15, 2010

PARTNER Trial Transcatheter Valve Results Will be Presented at TCT

September 15, 2010 – Results from the PARTNER Trial Cohort B will be presented at 11 a.m. on Thursday, Sept. 23, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium in Washington, D.C.

The PARTNER Trial is the world's first randomized clinical trial of a transcatheter heart valve and is studying the Edwards Lifesciences Corp. Sapien heart valve. Cohort B compares the Sapien to treatment with medical management in inoperable patients. The transcatheter valve is an investigational device in the United States and not yet available commercially in this country.

PARTNER is among the most important late-breaking trials being presented at TCT this year. TCT organizers said it has the potential to change how structural heart disease is treated in the future. The data presented will also factor into U.S. Food and Drug Administration (FDA) consideration of the Sapien device.

For more information:

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init